MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen

MeiraGTx Holdings plc

2024-Q1 EPS reported -$0.32 revenue$697,000

Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.
Cash and cash equivalents $119.2M at March 31; $138.9M after April collections; runway into Q1 2026.
Received $50M milestone from Janssen for Phase 3 LUMEOS extension study initiation for bota-vec in XLRP.
Phase 1 AQUAx data showed 112.8% increase in unstimulated saliva flow at 12 months; pivotal Phase 2 enrolling.
Completed dosing in Phase 1 bridging study for AAV-GAD Parkinson's gene therapy; Phase 3 design discussions in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

MeiraGTx Holdings plc reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001558370-24-007476

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.